PMID- 15981817
OWN - NLM
STAT- MEDLINE
DCOM- 20050719
LR  - 20151119
IS  - 0002-9173 (Print)
IS  - 0002-9173 (Linking)
VI  - 123
IP  - 5
DP  - 2005 May
TI  - Comparison of immunohistochemical and fluorescence in situ hybridization 
      assessment of HER-2 status in routine practice.
PG  - 766-70
AB  - Because HER-2 expression in invasive carcinoma of the breast has well-documented 
      ramifications for treatment and prognosis, accurate assessment of HER-2 status is 
      critical. Comparative studies have shown high concordance rates between 
      immunohistochemical analysis and fluorescence in situ hybridization (FISH) in 
      cases with immunohistochemical scores of 0 or 1+ (negative) and 3+ (strongly 
      positive) and low concordance rates among cases with immunohistochemical scores 
      of 2+. The present study was performed to determine concordance rates in a 
      setting more representative of routine clinical practice, in which multiple 
      pathologists submit specimens to a single cytogenetics referral laboratory. We 
      found a higher rate of discordance between immunohistochemical analysis and FISH 
      (approximately 92%) in the groups with immunohistochemical scores of 2+ than 
      reported in other studies. These results strongly support the practice of 
      performing FISH in all cases with immunohistochemical scores of 2+, particularly 
      in routine practice, in which interobserver variability in immunohistochemical 
      scoring among multiple pathologists is likely to be high.
FAU - Dolan, Michelle
AU  - Dolan M
AD  - Department of Laboratory Medicine and Pathology, University of Minnesota Medical 
      School, Minneapolis, MN 55455, USA.
FAU - Snover, Dale
AU  - Snover D
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
CIN - Am J Clin Pathol. 2006 Jan;125(1):155-6. PMID: 16483004
MH  - Biomarkers, Tumor/analysis
MH  - Breast Neoplasms/chemistry/*genetics/pathology
MH  - Carcinoma, Ductal, Breast/chemistry/*genetics/pathology
MH  - Carcinoma, Lobular/chemistry/*genetics/pathology
MH  - Humans
MH  - Immunohistochemistry/*methods
MH  - *In Situ Hybridization, Fluorescence
MH  - Observer Variation
MH  - Receptor, ErbB-2/analysis/*genetics
MH  - Reproducibility of Results
EDAT- 2005/06/29 09:00
MHDA- 2005/07/20 09:00
CRDT- 2005/06/29 09:00
PHST- 2005/06/29 09:00 [pubmed]
PHST- 2005/07/20 09:00 [medline]
PHST- 2005/06/29 09:00 [entrez]
PST - ppublish
SO  - Am J Clin Pathol. 2005 May;123(5):766-70.